1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
3 citations
,
October 2019 in “EMBO molecular medicine” Targeting NCoR1 can help treat heart enlargement and dysfunction.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
5 citations
,
January 2018 in “Indian Journal of Dermatology/Indian journal of dermatology” A woman got a skin rash from taking aceclofenac, which went away after she stopped the drug.
October 2007 in “Journal of Korean Medicine Rehabilitation” July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
January 2026 in “Dermatologic Therapy” Higher RBP4 levels are linked to severe alopecia areata, but genetic variant rs3758539 doesn't affect baricitinib response.
26 citations
,
October 2019 in “JNCI Cancer Spectrum” Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
January 2002 in “映像情報メディア学会技術報告” Some prostate cancers have gene changes that may affect treatment with certain drugs.
Different oral anticoagulants cause various non-bleeding side effects, so careful monitoring is needed.
May 2024 in “Indian Journal of Pharmacology” Tofacitinib effectively regrew scalp hair in an 11-year-old girl with alopecia areata.
June 2023 in “Lithuanian University of Health Sciences” Acne tarda is more common in women and those with darker skin, often linked to hormonal imbalances, and requires tailored treatment based on severity.
10 citations
,
September 2015 in “PLoS ONE” New mutations in the VDR gene cause vitamin D-resistant rickets without hair loss.
29 citations
,
July 2012 in “The Journal of Sexual Medicine” Rats had lasting erectile problems after stopping a certain medication.
March 2020 in “QJM: An International Journal of Medicine” SVF and PRP improve hair loss, but SVF causes more side effects.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
37 citations
,
October 2006 in “Archives of Biochemistry and Biophysics” A unique gene mutation causes vitamin D-resistant rickets without causing hair loss.
January 2024 in “Wiadomości Lekarskie” Pulmonary artery thrombectomy is safe and effective but not widely used.
October 2024 in “Journal of the Endocrine Society” Feminizing hormone therapy increases kidney filtration rate.
1 citations
,
March 2005 in “Zentralblatt für Gynäkologie” A postmenopausal woman had high testosterone from her right adrenal gland, leading to recommended surgery.
147 citations
,
October 2021 in “Cancer Communications” RC48 shows promise for treating certain advanced cancers, but more research is needed.
February 2025 in “Skin Appendage Disorders” Adrenal tumors can cause hair loss and high testosterone in women.
10 citations
,
December 2020 in “Frontiers in Medicine” Men are more at risk for severe COVID-19 due to biological differences, suggesting the need for targeted treatments.
May 2026 in “Applied Biochemistry and Biotechnology” Lemon-derived vesicles may help hair grow.
March 2025 in “AYUSHDHARA” Ayurvedic treatment with Gandharvahastadi Kwath improved thyroid dysfunction symptoms.
August 2013 in “Fertility and sterility” Metformin can help diagnose and treat high testosterone levels in women, often due to insulin resistance rather than a tumor.
December 2025 in “Drug Design Development and Therapy” Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.